10-Q: CannaPharmaRX Reports Q3 2024 Results, Revenue Growth Amidst Financial Challenges

CannaPharmaRX reports its first revenue, but also a net loss and ongoing concerns about its ability to continue as a going concern.

Summary

• CannaPharmaRX, a cannabis cultivation company, reported its financial results for the third quarter of 2024, showing its first revenue of $312,164 for the quarter and $338,003 for the nine months ended September 30, 2024.
• The company's cost of goods sold was $668,322 for the quarter and $1,582,026 for the nine months, resulting in a gross loss of $356,158 for the quarter and $1,244,023 for the nine months.
• Operating expenses were $141,788 for the quarter and $841,136 for the nine months, which included depreciation, general and administrative costs, payroll, consulting, and professional fees.
• The company experienced a net income of $188,421 for the quarter, but a net loss of $6,164,948 for the nine months ended September 30, 2024.
• The company's cash position is $6,999 as of September 30, 2024, with a working capital deficiency of $21,005,723, raising substantial doubt about its ability to continue as a going concern.
• The company is actively seeking additional funding through debt and equity financing to support its operations and growth.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a large net loss, substantial working capital deficiency, and concerns about the company's ability to continue as a going concern. While there are some positive developments, such as the start of revenue generation and new supply agreements, the overall financial situation is precarious.

Positives

• The company has commenced product sales and generated its first revenue.
• The company has secured supply agreements with Cantek Holdings and ICAN Green S.A. de C.V.
• The company has obtained its Israel Medical Cannabis (IMC) Good Agricultural Practices (GAP) and Good Agricultural and Collection Practices (GACP) certifications.
• The company has shipped its first product to a Canadian LP for distribution within Canada.
• The company has completed its first five grows and harvests are ready for sale.

Negatives

• The company has a significant working capital deficiency of $21,005,723.
• The company has an accumulated deficit of $97,443,301.
• The company has a net loss of $6,164,948 for the nine months ended September 30, 2024.
• The company has substantial doubt about its ability to continue as a going concern.
• The company has a loss on impairment of inventory of $529,634 for the nine months ended September 30, 2024.
• The company has a significant amount of debt, including promissory notes with high interest rates.
• The company has accrued liabilities for penalties on convertible notes amounting to $735,002.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company faces risks related to its ability to successfully commercialize its products and services.
• The company is subject to risks related to maintaining and developing relationships with customers and suppliers.
• The company faces risks related to integrating acquired businesses or new brands.
• The company is subject to risks related to competitive products and pricing.
• The company faces risks related to supply constraints or difficulties.
• The company is subject to risks related to the retention and availability of key personnel.
• The company faces risks related to general economic and business conditions.
• The company is subject to risks related to intellectual-property claims brought by third parties.
• The company faces risks related to industry regulation.
• The company has ongoing legal proceedings that could result in significant liabilities.

Future Outlook

The company anticipates developing a consistent cadence of growing, harvesting, cultivating, and delivering world class products on a regular basis and expects to begin to see a strong and accelerated revenue increase during the 2024 fiscal year. The company also plans to continue to collaborate with international partners, develop proprietary online technology, and expand its customer network.

Management Comments

• The company's production facility is operating at maximum capacity during FY2024, achieving regular plantings with staggered production.
• The company's focus continues to be on international sales with high gross margin products.
• The company will continue to collaborate with international partners on multiple continents and develop proprietary online, data-driven technology.
• The company's FY2024 growth goals were achieved and included delivering the first of several harvests during the first, second quarter.
• Additional goals for the remainder of FY2024 include continuing to increase our strategic partner network; receiving our European Union license for Good Manufacturing Practices (GMP) to allow us to expand distribution; expanding our customer network; becoming a world leader in unique genetic strains; and continuing to improve our balance sheet.

Industry Context

The company is operating in the cannabis industry, which is subject to evolving regulations and market conditions. The company's focus on international sales and unique genetic strains aligns with industry trends towards specialization and global expansion. The company's financial challenges are not uncommon in the cannabis industry, which often requires significant capital investment and faces regulatory hurdles.

Comparison to Industry Standards

• The company's revenue of $338,003 for the nine months ended September 30, 2024, is low compared to established cannabis companies, such as Canopy Growth Corporation, which reported net revenue of $70.1 million CAD in its most recent quarter.
• The company's gross loss of $1,244,023 for the nine months ended September 30, 2024, indicates significant challenges in achieving profitability, which is a common issue for early-stage cannabis companies.
• The company's operating expenses of $841,136 for the nine months ended September 30, 2024, are relatively high compared to its revenue, highlighting the need for cost management.
• The company's cash balance of $6,999 as of September 30, 2024, is extremely low compared to industry standards, indicating a critical need for additional funding.
• The company's working capital deficiency of $21,005,723 as of September 30, 2024, is a significant concern, as many cannabis companies have positive working capital.
• The company's accumulated deficit of $97,443,301 as of September 30, 2024, is substantial, reflecting the challenges of achieving profitability in the cannabis industry.
• The company's reliance on debt financing with high interest rates is a common practice for early-stage cannabis companies, but it also increases financial risk.
• The company's legal proceedings are a significant risk, as many cannabis companies face litigation related to contracts, intellectual property, and regulatory compliance.

Legal Proceedings

• The company is involved in a legal action with Ataraxia Canada, Inc., seeking $15 million in damages.
• The company is involved in a legal action with Bristol Capital Investors, LLC, seeking $10.5 million in damages.
• The company is involved in a legal action with Deloitte LLP, seeking recovery of unpaid fees.
• Former executives of the company John Cassels and Andrew Steedman have filed a lawsuit against the company alleging damages and back pay due to them.

Related Party Transactions

• The company has a $13,642 interest-free loan from a company owned by a director.
• The company has a $450,000 promissory note with a shareholder of the company.
• The company has an obligation to issue additional Class C preferred shares to a shareholder as part of the LTB transaction.
• The company leases office space from a company to which a director serves as a director.
• The company has balances owing to a company controlled by the CFO for accounting services.
• The company has balances owing to the chairman of the board of directors for unpaid directors fees.
• The company has balances owing to a director for unpaid salary and expense reimbursement amounts.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial challenges and potential dilution from equity financing.
• Employees face uncertainty due to the company's financial instability and potential for restructuring.
• Customers may be impacted by the company's ability to fulfill supply agreements.
• Suppliers may face risk of non-payment due to the company's financial difficulties.
• Creditors face risk of non-payment due to the company's financial instability.

Next Steps

• The company plans to continue to increase its strategic partner network.
• The company plans to receive its European Union license for Good Manufacturing Practices (GMP).
• The company plans to expand its customer network.
• The company plans to become a world leader in unique genetic strains.
• The company plans to continue to improve its balance sheet.
• The company plans to engage in further research and development.
• The company plans to raise additional capital in the short term.

Key Dates

Keywords

cannabis, cultivation, revenue, net loss, operating expenses, going concern, debt, equity financing, supply agreements, licenses, inventory, promissory notes, convertible notes